Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INS001
MIFTS: 66

Insulinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Insulinoma

About this section

MalaCards integrated aliases for Insulinoma:

Name: Insulinoma 39 12 77 54 60 30 56 6 45 15 17 74
Islet Cell Adenoma 12 74
Experimental Organism Islet Cell Adenoma Neoplasm 74
Insulin-Producing Tumor of Islet Cells 12
Adenoma Islet Cell 56
Islet Cell Tumor 74

Characteristics:

Orphanet epidemiological data:

60
insulinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Ireland),1-9/1000000 (Worldwide),1-9/1000000 (Japan); Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare gastroenterological diseases
Rare endocrine diseases


Sources

Summaries for Insulinoma

About this section
NIH Rare Diseases : 54 Insulinoma is a type of pancreatic neuroendocrine tumor (pancreatic NET), which refers to a group of rare tumors that form in the hormone-making cells of the pancreas. Insulinomas, specifically, produce too much insulin, a hormone that reduces the level of sugar in the blood by helping it move into cells. As a result, people with insulinomas generally have very low blood sugar levels which can be associated with anxiety, confusion, hunger, a fast heart rate, and sweating. In severe cases, it can lead to seizures, coma or even death. Ninty percent of insulinomas are benign (noncancerous). In most cases, the underlying cause of insulinoma is unknown. However, people with specific genetic syndromes such as multiple endocrine neoplasia type I, Von Hippel-Lindau syndrome, Neurofibromatosis type 1, and tuberous sclerosis are at risk of insulinomas and other endocrine tumors. Treatment generally includes surgery to remove the tumor.

MalaCards based summary : Insulinoma, also known as islet cell adenoma, is related to insulinomatosis and diabetes mellitus and multiple endocrine neoplasia, type i. An important gene associated with Insulinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Glucose / Energy Metabolism. The drugs Pancrelipase and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and liver, and related phenotypes are hyperhidrosis and seizures

Disease Ontology : 12 An adenoma that is located in the pancreas and is characterized by overproduction of insulin.

Wikipedia : 77 An insulinoma is a tumor of the pancreas that is derived from beta cells and secretes insulin. It is a... more...

Sources

Related Diseases for Insulinoma

About this section

Diseases related to Insulinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 insulinomatosis and diabetes mellitus 31.4 ABCC8 INS SCT SST
2 multiple endocrine neoplasia, type i 30.9 INS MEN1 SCT SST
3 glucagonoma 30.8 SCT SST
4 hypoglycemia 30.6 ABCC8 GCG GCK INS
5 gastrinoma 30.5 INS MEN1 SCT SST
6 hyperproinsulinemia 30.3 INS SCT
7 zollinger-ellison syndrome 30.3 MEN1 SCT SST
8 neuroendocrine tumor 30.2 INSM1 MEN1 SST SSTR2
9 hyperinsulinism 30.1 ABCC8 GCK INS SST
10 islet cell tumor 30.1 IAPP INS MEN1 SST
11 glucose intolerance 30.1 GCG GCK INS
12 hyperinsulinemic hypoglycemia 29.9 ABCC8 GCK INS MEN1 SST
13 duodenal ulcer 29.9 INS SCT SST
14 dumping syndrome 29.5 GCG INS SCT SST
15 small cell cancer of the lung 29.5 INSM1 SST SSTR2
16 pituitary adenoma, prolactin-secreting 29.3 MEN1 SST SSTR2 SSTR5
17 body mass index quantitative trait locus 11 28.9 GCG GCK GLP1R IAPP INS SLC2A2
18 diabetes mellitus, insulin-dependent 28.9 GCG GCK IAPP INS PTPRN SST
19 diabetes mellitus 28.0 ABCC8 GCG GCK GLP1R IAPP INS
20 hyperglycemia 27.9 ABCC8 GCG GCK GLP1R IAPP INS
21 diabetes mellitus, noninsulin-dependent 27.8 ABCC8 GCG GCK GLP1R IAPP INS
22 insulinoma tumor suppressor gene locus 12.2
23 metastatic insulinoma 12.2
24 adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia 12.1
25 pancreatic neuroendocrine tumor 11.5
26 neuroblastoma 10.6
27 multiple endocrine neoplasia 10.5
28 microinvasive cervical squamous cell carcinoma 10.4 INSM1 PTPRN
29 fallopian tube endometrioid adenocarcinoma 10.4 INSM1 PTPRN
30 pancreatic gastrinoma 10.4 MEN1 SCT
31 pancreatic somatostatinoma 10.4 MEN1 SST
32 epilepsy 10.4
33 intestinal neuroendocrine benign tumor 10.4 MEN1 SCT
34 duodenal somatostatinoma 10.4 INS SST
35 small intestine neuroendocrine neoplasm 10.4 MEN1 SCT
36 postgastrectomy syndrome 10.3 INS SST
37 fallopian tube adenocarcinoma 10.3 INSM1 PTPRN
38 type 1 diabetes mellitus 7 10.3 INS PTPRN
39 endocrine organ benign neoplasm 10.3 INS MEN1 SST
40 pituitary gland disease 10.3 INS MEN1 SST
41 type 1 diabetes mellitus 13 10.3 INS PTPRN
42 type 1 diabetes mellitus 15 10.2 GCG INS
43 adenoma of pancreas 10.2
44 autosomal genetic disease 10.2 GCK INS MEN1
45 pancreatic agenesis 1 10.2 PDX1 SCT
46 duodenal gastrinoma 10.2 MEN1 SCT SST
47 hyperpituitarism 10.2 INS SST
48 hyperinsulinemic hypoglycemia, familial, 7 10.2 GCG INS
49 small intestine cancer 10.2 MEN1 SCT SST
50 maturity-onset diabetes of the young, type 9 10.2 GCG INS

Graphical network of the top 20 diseases related to Insulinoma:



Diseases related to Insulinoma
Sources

Symptoms & Phenotypes for Insulinoma

About this section

Human phenotypes related to Insulinoma:

60 33 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000975
2 seizures 60 33 hallmark (90%) Very frequent (99-80%) HP:0001250
3 tremor 60 33 hallmark (90%) Very frequent (99-80%) HP:0001337
4 hyperinsulinemic hypoglycemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0000825
5 fasting hyperinsulinemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0008283
6 recurrent hypoglycemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001988
7 transient global amnesia 60 33 hallmark (90%) Very frequent (99-80%) HP:0010534
8 palpitations 60 33 hallmark (90%) Very frequent (99-80%) HP:0001962
9 nonketotic hypoglycemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001958
10 abnormality of the pancreatic islet cells 60 33 hallmark (90%) Very frequent (99-80%) HP:0006476
11 generalized muscle weakness 60 33 frequent (33%) Frequent (79-30%) HP:0003324
12 zollinger-ellison syndrome 60 33 frequent (33%) Frequent (79-30%) HP:0002044
13 pituitary prolactin cell adenoma 60 33 frequent (33%) Frequent (79-30%) HP:0006767
14 increased body weight 60 33 frequent (33%) Frequent (79-30%) HP:0004324
15 polyphagia 60 33 frequent (33%) Frequent (79-30%) HP:0002591
16 reactive hypoglycemia 60 33 frequent (33%) Frequent (79-30%) HP:0012051
17 primary hyperparathyroidism 60 33 frequent (33%) Frequent (79-30%) HP:0008200
18 fluctuations in consciousness 60 33 frequent (33%) Frequent (79-30%) HP:0007159
19 fatigue 60 33 occasional (7.5%) Occasional (29-5%) HP:0012378
20 abnormality of vision 60 33 occasional (7.5%) Occasional (29-5%) HP:0000504
21 hearing abnormality 60 33 occasional (7.5%) Occasional (29-5%) HP:0000364
22 anxiety 60 33 occasional (7.5%) Occasional (29-5%) HP:0000739
23 paresthesia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003401
24 neuroendocrine neoplasm 60 33 occasional (7.5%) Occasional (29-5%) HP:0100634
25 coma 60 33 occasional (7.5%) Occasional (29-5%) HP:0001259
26 insomnia 60 33 occasional (7.5%) Occasional (29-5%) HP:0100785
27 lethargy 60 33 occasional (7.5%) Occasional (29-5%) HP:0001254
28 neoplasm of the adrenal gland 60 33 occasional (7.5%) Occasional (29-5%) HP:0100631
29 abnormal rapid eye movement sleep 60 33 occasional (7.5%) Occasional (29-5%) HP:0002494
30 abnormality of pain sensation 60 33 occasional (7.5%) Occasional (29-5%) HP:0010832
31 behavioral abnormality 60 Frequent (79-30%)
32 reduced consciousness/confusion 60 Frequent (79-30%)
33 hyperinsulinemia 60 Very frequent (99-80%)
34 abnormality of higher mental function 60 Occasional (29-5%)

MGI Mouse Phenotypes related to Insulinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.9 ABCC8 GCK GLP1R INS INSM1 MEN1
2 digestive/alimentary MP:0005381 9.8 INS INSM1 MEN1 PDX1 SST SSTR2
3 growth/size/body region MP:0005378 9.7 GCK GLP1R IAPP INS INSM1 MEN1
4 homeostasis/metabolism MP:0005376 9.5 ABCC8 GCK GLP1R IAPP INS INSM1
Sources

Drugs & Therapeutics for Insulinoma

About this section

Drugs for Insulinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
2
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177 70789204
6
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
7
Pasireotide Approved Phase 4,Phase 2,Phase 1 396091-73-9 9941444
8
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051
9 Fluorodeoxyglucose F18 Phase 4,Phase 2
10 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
11 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Hypoglycemic Agents Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Insulin, Globin Zinc Phase 4,Phase 2,Not Applicable
25 insulin Phase 4,Phase 2,Not Applicable
26
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
27
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 6857599 5310940 9887054 43805
28
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
29
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
30
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
31
Cinacalcet Approved Phase 3 226256-56-0 156419
32
Parathyroid hormone Approved, Investigational Phase 3,Phase 1 9002-64-6
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
34
lanreotide Approved Phase 3,Phase 2 108736-35-2
35
Dopamine Approved Phase 3,Phase 1 62-31-7, 51-61-6 681
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
37
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1 7440-70-2 271
38 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
39 Antimetabolites Phase 2, Phase 3,Phase 1
40 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1
41 Folate Phase 2, Phase 3
42 Vitamin B9 Phase 2, Phase 3
43 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
44 Central Nervous System Depressants Phase 3,Phase 2,Not Applicable
45 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
46 Calcium, Dietary Phase 3,Phase 2,Phase 1
47 Calcimimetic Agents Phase 3
48 Analgesics, Opioid Phase 3
49 Peripheral Nervous System Agents Phase 3,Phase 2
50 Cola Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Nonfunctional Pancreatic NET and PET Imaging Unknown status NCT02621541 Phase 4
3 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
4 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
5 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
6 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
7 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
10 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
11 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
12 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
13 Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Surufatinib
14 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
15 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
16 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
17 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
18 Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
19 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Unknown status NCT01803503 Phase 2 Docetaxel;Sunitinib
20 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
21 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
22 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
23 Effect of Gelofusine on GLP1-receptor Imaging Completed NCT02541734 Phase 1, Phase 2 Gelofusine;Placebo
24 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
25 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
26 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
27 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
28 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
29 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
30 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
31 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
32 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
33 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
34 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
35 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
36 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
37 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01121562 Phase 2 Sunitinib
38 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
39 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
40 A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Completed NCT02305810 Phase 2 Everolimus 10 mg daily
41 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
42 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
43 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Completed NCT01673906 Phase 2 Diagnostic work up
44 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
45 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
46 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 satoreotide trizoxetan
47 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
48 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
49 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
50 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib

Search NIH Clinical Center for Insulinoma

Cochrane evidence based reviews: insulinoma

Sources

Genetic Tests for Insulinoma

About this section

Genetic tests related to Insulinoma:

# Genetic test Affiliating Genes
1 Insulinoma 30
Sources

Anatomical Context for Insulinoma

About this section

MalaCards organs/tissues related to Insulinoma:

42
Pancreas, Liver, Pancreatic Islet, Testes, Heart, Lung, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Insulinoma:

20
The Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Insulinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease
Sources

Publications for Insulinoma

About this section

Articles related to Insulinoma:

(show top 50) (show all 1936)
# Title Authors Year
1
Letters about Published Papers Letters of comment about recently published papers should be sent by email to: bgoldspiel@verizon.net. ( 30760166 )
2019
2
A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult Hypoglycemia. ( 30597028 )
2019
3
Transarterial Embolization for Mitigation of Severe Hypoglycemia in 2 Patients with Primary Pancreatic Insulinoma. ( 30819499 )
2019
4
Characterization of Transplantable Insulinoma Cells. ( 30535698 )
2019
5
Vitronectin, fibronectin and epidermal growth factor induce proliferation via the JNK and ERK pathways in insulinoma INS-1 cells. ( 30603922 )
2019
6
Early 18F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. ( 30617961 )
2019
7
Rab8a is involved in membrane trafficking of Kir6.2 in the MIN6 insulinoma cell line. ( 30631919 )
2019
8
Endoscopic ultrasound-guided fine needle injection of alcohol for ablation of an insulinoma: a well documented successful procedure. ( 30634191 )
2019
9
Metastatic Insulinoma Presenting as a Liver Cyst. ( 30646672 )
2019
10
Negative Effects of Cyclic Palmitate Treatment on Glucose Responsiveness and Insulin Production in Mouse Insulinoma Min6 Cells Are Reversible. ( 30702352 )
2019
11
5'-Iodotubercidin represses insulinoma associated-1 expression, decreases cAMP levels, and suppresses human neuroblastoma cell growth. ( 30755485 )
2019
12
Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome. ( 30789400 )
2019
13
Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study. ( 30808334 )
2019
14
Genetic obesity increases pancreatic expression of mitochondrial proteins which regulate cholesterol efflux in BRIN-BD11 insulinoma cells. ( 30819824 )
2019
15
Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. ( 30850220 )
2019
16
Insulinoma resembling a rapid eye movement sleep behavior disorder: a case report. ( 30863190 )
2019
17
Candidate plasticity gene 16 mediates suppression of insulin gene expression in rat insulinoma INS-1 cells under glucotoxic conditions. ( 30879761 )
2019
18
Biochemical and Clinical Features of Insulinoma in a Patient with Turner Syndrome. ( 30881705 )
2019
19
Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT. ( 30889001 )
2019
20
Insulin secretion in response to high extracellular calcium is not a pathognomonic feature of insulinoma cells. ( 29097005 )
2019
21
Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. ( 29691623 )
2018
22
Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. ( 29923016 )
2018
23
Probing the Effect of Physiological Concentrations of IL-6 on Insulin Secretion by INS-1 832/3 Insulinoma Cells under Diabetic-Like Conditions. ( 29966345 )
2018
24
Glucose Management during Insulinoma Resection Using Real-Time Subcutaneous Continuous Glucose Monitoring. ( 29977620 )
2018
25
<i>Nfe2l1-</i> silenced insulinoma cells acquire aggressiveness and chemoresistance. ( 29203613 )
2018
26
Insulinoma presenting with post-prandial hypoglycaemia following fundoplication. ( 29367876 )
2018
27
Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. ( 29360191 )
2018
28
Pro-inflammatory cytokines attenuate glucose-stimulated insulin secretion from INS-1E insulinoma cells by restricting mitochondrial pyruvate oxidation capacity - Novel mechanistic insight from real-time analysis of oxidative phosphorylation. ( 29953508 )
2018
29
Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology. ( 29936498 )
2018
30
Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). ( 29148079 )
2018
31
Robotic enucleation for pediatric insulinoma with MEN1 syndrome: a case report and literature review. ( 29921249 )
2018
32
Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review. ( 29662318 )
2018
33
Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. ( 29885405 )
2018
34
Akt/p27<sup>kip1</sup> Pathway Is Not Involved in Human Insulinoma Tumorigenesis. ( 29853883 )
2018
35
The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring. ( 29877259 )
2018
36
Screening key candidate genes and pathways involved in insulinoma by microarray analysis. ( 29851790 )
2018
37
Arterial calcium stimulation with hepatic venous sampling predicts the localization and size of the insulinoma as well as postoperative weight loss. ( 29966460 )
2018
38
Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. ( 29175872 )
2018
39
Utility of contrast-enhanced computed tomography in the evaluation of canine insulinoma location. ( 29806550 )
2018
40
17I^-estradiol protects INS-1 insulinoma cells from mitophagy via G protein-coupled estrogen receptors and the PI3K/Akt signaling pathway. ( 29436590 )
2018
41
Diagnostic challenges in a patient with an occult insulinoma:<sup>68A </sup>Ga-DOTA-exendin-4 PET/CT and <sup>68</sup>Ga-DOTATATE PET/CT. ( 29636947 )
2018
42
Clinical Value of<sup>18</sup>F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. ( 29277794 )
2018
43
Insulinoma Masquerading as Transient Neurocognitive Impairment. ( 29753794 )
2018
44
Contrast-enhanced harmonic endoscopic ultrasound: A better choice to guide EUS-FNI for insulinoma. ( 29776875 )
2018
45
An observational analysis of insulinoma from 1 single institution. ( 29319794 )
2018
46
68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia. ( 29877881 )
2018
47
Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. ( 29314520 )
2018
48
Hypoglycemia caused by insulinoma. A review of a case series treated at a tertiary hospital. ( 29657066 )
2018
49
Hyperinsulinemic hypoglycemia without insulinoma: Think of activating glucokinase mutation. ( 29555163 )
2018
50
Peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. ( 29949120 )
2018
Sources

Variations for Insulinoma

About this section

ClinVar genetic disease variations for Insulinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MEN1 NM_000244.3(MEN1): c.371_372delTC (p.Val124Aspfs) deletion Pathogenic rs1555166368 GRCh38 Chromosome 11, 64809738: 64809739
2 MEN1 NM_000244.3(MEN1): c.371_372delTC (p.Val124Aspfs) deletion Pathogenic rs1555166368 GRCh37 Chromosome 11, 64577210: 64577211
Sources

Expression for Insulinoma

About this section
Search GEO for disease gene expression data for Insulinoma.
Sources

Pathways for Insulinoma

About this section

Pathways related to Insulinoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 38
Show member pathways
 12.67 ABCC8 GCG GCK GLP1R INS PDX1
2
Glucose / Energy Metabolism 4
12.29 GCG INS PDX1 WFS1
3
Presynaptic function of Kainate receptors 67
Show member pathways
 12.13 GCG GLP1R IAPP SCT
4
Integration of energy metabolism 67
Show member pathways
 12.08 ABCC8 GCG GLP1R INS SLC2A2
5
G alpha (s) signalling events 67
11.87 GCG GLP1R IAPP SCT
6
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.81 INS PDX1 SLC2A2
7
Hepatic ABC Transporters 65
Show member pathways
 11.76 GCK INS PDX1 SLC2A2
8
Glucagon signaling pathway 38
11.65 GCG GCK SLC2A2
9
Type II diabetes mellitus 38 1
Show member pathways
 11.54 ABCC8 GCK INS PDX1 SLC2A2
10
Regulation of beta-cell development 67
Show member pathways
 11.1 GCK IAPP INS INSM1 PDX1 SLC2A2
11
FOXA2 and FOXA3 transcription factor networks 1
11 ABCC8 GCK INS PDX1 SLC2A2
12
Cori Cycle 1
10.68 INS SLC2A2
Sources

GO Terms for Insulinoma

About this section

Cellular components related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.92 GCG INS MEN1 WFS1

Biological processes related to Insulinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.92 GCG GLP1R IAPP INS SCT SST
2 regulation of signaling receptor activity GO:0010469 9.89 GCG IAPP INS SCT SST
3 cellular protein metabolic process GO:0044267 9.81 IAPP INS MEN1 WFS1
4 negative regulation of cell proliferation GO:0008285 9.73 INSM1 MEN1 PDX1 SST SSTR2 SSTR5
5 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.71 GCG GLP1R IAPP
6 glucose metabolic process GO:0006006 9.65 GCK INS PDX1
7 cellular response to glucocorticoid stimulus GO:0071385 9.58 SSTR2 SSTR5
8 cellular glucose homeostasis GO:0001678 9.57 ABCC8 GCK
9 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.56 PDX1 WFS1
10 positive regulation of glycogen biosynthetic process GO:0045725 9.55 GCK INS
11 glucose homeostasis GO:0042593 9.55 GCK INS PDX1 SSTR5 WFS1
12 negative regulation of gluconeogenesis GO:0045721 9.52 GCK INS
13 negative regulation of type B pancreatic cell apoptotic process GO:2000675 9.46 PDX1 WFS1
14 regulation of potassium ion transport GO:0043266 9.43 GCK KCNA5
15 somatostatin signaling pathway GO:0038170 9.4 SSTR2 SSTR5
16 detection of glucose GO:0051594 9.37 GCK PDX1
17 regulation of insulin secretion GO:0050796 9.17 ABCC8 GCG GCK GLP1R KCNA5 SLC2A2
18 type B pancreatic cell differentiation GO:0003309 9.13 INSM1 MEN1 PDX1

Molecular functions related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 9.16 SSTR2 SSTR5
2 hormone activity GO:0005179 9.02 GCG IAPP INS SCT SST
3 somatostatin receptor activity GO:0004994 8.96 SSTR2 SSTR5
Sources

Sources for Insulinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....